ClinicalTrials.gg
TerminatedNCT03516084Updated Dec 21, 2020

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

A Phase 3 interventional study of ZL-2306(nirapairb) and Placebo in Extensive-stage Small Cell Lung Cancer, sponsored by Zai Lab (Shanghai) Co., Ltd.. Terminated at 33 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 3, Interventional, and Treatment

Why this study was terminated
As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment speed significantly lower than expected, ZaiLab decided to terminate this study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
91st of 333
185 · median 63
Started
2018
with 15 others
Phase 3
57 of 365
23 open now
Registered
50th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 91st largest by enrollment of the 333 interventional ones that give a count, is one of 16 that started in 2018, is one of 57 in phase 3, and was the 50th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients with extensive-stage disease small cell lung cancer (ED-SCLC) to evaluate the efficacy and safety.

03

Conditions studied

  • Extensive-stage Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aged 18-75 years

or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC)

Ongoing clinical benefit (partial response [PR], or complete response [CR] per version 1.1) following completion of 4 cycles of platinum-based therapy (cisplatin or carboplatin, plus etoposide)

(ECOG) performance status of 0 or 1

Subjects must have adequate bone marrow, renal and hepatic function

Exclusion criteria

Exclusion Criteria:

Subjects with Central Nervous System (CNS)

Subjects receiving consolidative chest radiation after last dose of chemotherapy.

Subjects with pleural effusions that cannot be controlled with appropriate interventions.

All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    ZL-2306(nirapairb)

    Drug: ZL-2306(nirapairb)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.

  • DrugPlacebo

    The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.

06

What researchers measure

Primary outcomes

  1. BICR-assessed progression-free survival (PFS)

    The time assessed by the Blinded Independent Central Review (BICR) from randomization to progressive disease or death due to various causes, whichever occurs; progressive disease will be assessed in accordance with RECIST 1.1 criteria.

    Time frame: Approximately 14 months since the first subject enrolled

  2. Overall survival (OS)

    The time from randomization to death due to any cause.

    Time frame: Approximately 48 months since first subject enrolled

Secondary outcomes

  1. Investigator-assessed PFS

    the investigator-assessed time from randomization to progressive disease or death due to various causes, whichever occurs; progressive disease will be assessed in accordance with RECIST 1.1 criteria.

    Time frame: Approximately 14 months since the first subject enrolled

Other outcomes

  1. Change in patient reported outcomes (PROs)--physical functioning domain

    Evaluations of the quality of life of patients with small cell lung cancer include summary and analysis of absolute values and changes from baseline of various fields and single items in the patient-completed EORTC questionnaire QLQ-C30 (Version 3.0) and QLQ-LC13 Chinese version to evaluate the quality of life of lung cancer patients in the treatment group and the control group.

    Time frame: Approximately 48 months since first subject enrolled

07

Study locations

33 sites
  • Anhui Provincal Hospital
    Hefei, Anhui, China
  • Beijing Cancer Hospital
    Beijing, Beijing, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing, China
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing, China
  • Hospital, Academy of Military Medical Sciences
    Beijing, Beijing, China
  • Peking union medical college hospital
    Beijing, Beijing, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Nanfang Hospital
    Guangzhou, Guangdong, China
  • The first affiliated hospital of Guangzhou medical school
    Guangzhou, Guangdong, China
  • The first affiliated hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Union hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • The second xiangya hospital of central south university
    Changsha, Hunan, China
  • Nanjing General Hospital
    Nankín, Jiangsu, China
  • Nantong Tumor Hospital
    Nantong, Jiangsu, China
  • The first affiliated hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Jinzhou Central Hospital
    Jinzhou, Liaoning, China
  • China shenyang chest hospital
    Shenyang, Liaoning, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
  • Lin Yi Cancer Hospital
    Linyi, Shandong, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
  • Shanghai Chest Hospital, Shanghai Jiao Tong University
    Shanghai, Shanghai, China
  • Tangdu Hospital
    Xi'an, Shanxi, China
  • Xinjiang Cancer Hospital
    Ürümqi, Xinjiang, China
  • Second Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang, China
  • Zhejiang cancer hospital
    Hangzhou, Zhejiang, China
  • First Affiliated Hospital, Zhejiang University
    Hanzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Feb 2020, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2018
First posted
May 4, 2018
StartActual
Aug 20, 2018
Primary completionActual
Feb 21, 2020
CompletionActual
Mar 20, 2020
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03516084
Responsible party
Sponsor
First posted
May 4, 2018
Start date
Aug 20, 2018
Primary completion
Feb 21, 2020
Completion
Mar 20, 2020
Last update
Dec 21, 2020

Study contacts

Zai Lab
study director · Zai Lab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion